RxDoctor Payments Data

Ann Rogers

Family · Omaha, NENPI 1891204871

Payments from drug & device makers

$2,431in general payments, 2019–2025

Across 117 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$896
  • Johnson & Johnson$385
  • Mallinckrodt Hospital Products Inc.$376
  • Pfizer$196
  • Lilly USA, LLC$173
  • Aurinia Pharma U.S., Inc.$123
  • plus $284 from 9 others

What the payments were for

  • Food & beverage$2,19290%
  • Education$23910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,431 in reported general payments places this provider in the 85th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$20,054
Medicare patients
137
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept11$109,166
EnbrelEtanercept12$90,496
Celecoxib88$4,512
Hydroxychloroquine Sulfate120$3,704
MethotrexateMethotrexate Sodium99$2,799
Cevimeline Hcl14$2,343
Gabapentin47$813
Leflunomide20$584
Prednisone104$576
Pregabalin26$533
Duloxetine Hcl32$420
Tramadol Hcl38$407
Sulindac16$399
Allopurinol45$374
Diclofenac Sodium16$269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$896$90,49612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 809 family providers in Nebraska.

Other family in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →